Suchergebnisse - "Ding, Kaiyang"

PubPharm (59)

1

Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B) : a single-arm, multinational, phase 2 study

enthalten in: The Lancet. Oncology | 2024

von Song, Y. | Malpica, L. | Cai, Q. | +30

2

Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma : A phase 2, multicenter, open-label study

enthalten in: American journal of hematology | 2023

von Deng, L. | Li, Z. | Zhang, H. | +30

3

Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma : a multicenter phase II trial

enthalten in: Haematologica | 2023

von Ding, K. | Liu, H. | Ma, J. | +10

CommentIn: Haematologica. 2023 Aug 01;108(8):1984-1985. - PMID 37021531

4

Improved Artificial Potential Field Algorithm Assisted by Multisource Data for AUV Path Planning

enthalten in: Sensors (Basel, Switzerland) | 2023

von Xing, T. | Wang, X. | Ding, K. | +2

5

Clinical characteristics and outcomes of follicular lymphoma patients with extranodal involvement : analysis of a series of 1090 cases in China

enthalten in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2023

von Lin, Z. | Zha, J. | Yi, S. | +20

6

Chidamide-BEAC plus autologous stem cell transplantation in high-risk non-Hodgkin lymphoma : a phase II clinical trial

enthalten in: Chinese medical journal | 2023

von Xia, Y. | Wang, L. | Ding, K. | +10

7

Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201) : Results From a Single-Arm, Multicenter, Phase II Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Huang, H. | Tao, R. | Hao, S. | +22

8

Real-world data for lenalidomide maintenance in responding patients of diffuse large B-cell lymphoma

enthalten in: Cancer medicine | 2023

von Wang, X. | Yu, L. | Jiang, X. | +1

9

Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients : Multi-center, single-arm, open-label, phase 2 study

enthalten in: American journal of hematology | 2023

von Xu, W. | Zhou, K. | Wang, T. | +22

10

Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment : An open-label, single-agent, multicenter study in China

enthalten in: Cancer | 2023

von Gao, Y. | Liu, Y. | Wang, Y. | +20

1
2
3
4
5
6
Nächster »
[6]